- Title
- Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation
- Creator
- Joshi, Maansi; Taper, John; Huang, Gillian; Hertzberg, Mark; Forsyth, Cecily; Rowlings, Philip; Campbell, Philip; Crispin, Philip; Harvey, Michael; Underhill, Craig; Bayley, Angela; Byth, Karen
- Relation
- Leukemia & Lymphoma Vol. 61, Issue 1, p. 91-97
- Publisher Link
- http://dx.doi.org/10.1080/10428194.2019.1660968
- Publisher
- Taylor & Francis
- Resource Type
- journal article
- Date
- 2020
- Description
- Patients with relapsed-refractory diffuse large B-cell lymphoma (RR-DLBCL) ineligible for autologous stem cell transplantation (autoSCT) have poor survival. Thirty transplant-ineligible patients older than 60 years were administered rituximab 375 mg/m2 day 1, ifosfamide 1333 mg/m2 days 1 to 3, and etoposide 80 mg/m2 days 1 to 3 (R-IE) every 21 days for 6 cycles plus 2 doses of rituximab. Revised international prognostic index 3–4 was seen in 53% and prior rituximab exposure in 60%. The complete and overall response rates were 55% and 76%, respectively. Median progression free survival (PFS) and overall survival were 23 and 24 months, respectively. Patients relapsing within 12 months of prior treatment had a median PFS of 2.5 months compared to 23 months for those relapsing beyond 12 months. Grade 3–4 thrombocytopenia and neutropenia occurred in one and eight patients, respectively. R-IE is an effective, well tolerated regimen in RR-DLBCL patients not fit for autoSCT.
- Subject
- large cell lymphoma; relapsed; refractory; patients; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1461448
- Identifier
- uon:46198
- Identifier
- ISSN:1042-8194
- Language
- eng
- Reviewed
- Hits: 2857
- Visitors: 2854
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|